ACE2 and COVID-19: As IL‐13 is associated with fast viral clearance [29] and patients with asthma driven by IL‐13 have a lower risk of death by COVID‐19 [30], the presence of a persistent concentration of IL‐13 in vaccinated or convalescent individuals may confer an advantage in the case of exposure to SARS‐CoV‐2, e.g. by down‐regulating ACE2 expression and attenuation of viral entry, replication, and spreading [31, 32, 33].